Business Context and Reporting Period
Actinium Pharmaceuticals, Inc. (ATNM) filed this Form 8-K on April 29, 2020, reporting a material event regarding its listing status on the NYSE American. The company is a Delaware corporation headquartered in New York, NY.
Key Financial Metrics
This filing is a current report regarding a regulatory compliance issue and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the receipt of a deficiency letter from the NYSE American on April 29, 2020. The exchange determined the company is not in compliance with Section 1003(f)(v) of the NYSE American Company Guide because its common shares have been selling at a low price per share for a substantial period. This deficiency does not result in immediate delisting but subjects the company to Section 1009 procedures, which could lead to delisting proceedings if not cured.
Outlook, Risks, and Management Commentary
- Compliance Deadline: The NYSE American staff has set a deadline of October 29, 2020, for the company to demonstrate sustained price improvement or effect a reverse stock split to regain compliance.
- Management Response: The company intends to undertake measures deemed in the best interests of the company and its shareholders to cure the deficiency.
- Operational Impact: Management states that the receipt of the letter does not affect the company's business, operations, or SEC reporting requirements.
- Risk: Failure to cure the deficiency by the deadline could result in the initiation of delisting proceedings.
Investor Verification Checklist
- Verify the current trading price of ATNM to assess the severity of the low-price deficiency.
- Monitor upcoming announcements regarding a potential reverse stock split or other capital structure changes.
- Track the company's progress toward the October 29, 2020, compliance deadline.
- Review subsequent filings for any updates on the status of the deficiency letter or delisting proceedings.